Retatrutide: What Lilly’s Triple-Agonist Drug Means for Weight Loss Treatment
Let me start with a number that should get your attention: 28.7%. That’s how much body weight participants lost in the latest Phase 3 trial of retatrutide, Eli Lilly’s investigational triple-agonist obesity medication. At 68 weeks, the average weight loss…
